Identification and characterization of Marek's disease virus serotype 1 (MDV1) ICP22 gene product: MDV1 ICP22 transactivates the MDV1 ICP27 promoter synergistically with MDV1 ICP4

Veterinary Microbiology

Volumn 85, Issue 4, 2002, Pages 305-313

  Kato, Kentaro ^a,b   Izumiya, Yoshihiro ^b   Tohya, Yukinobu ^b   Takahashi, Eiji ^b   Hirai, Kanji ^a   Kawaguchi, Yasushi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

ICP22; ICP4; Marek's disease virus

Indexed keywords

BUTYRIC ACID; EPITOPE; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; AVIAN LYMPHOMATOSIS HERPETOVIRUS; BACULOVIRUS EXPRESSION SYSTEM; BIOASSAY; BIRD DISEASE; CHICKEN; CONTROLLED STUDY; EMBRYO; FIBROBLAST; GENETIC CODE; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; SEROTYPE; SEROTYPING; SIMIAN VIRUS; TRANSACTIVATION; VIRUS CHARACTERIZATION; VIRUS EXPRESSION; VIRUS GENE; VIRUS IDENTIFICATION;

ANIMALS; BACULOVIRIDAE; CHICK EMBRYO; CHICKENS; COS CELLS; FIBROBLASTS; GENE EXPRESSION REGULATION, VIRAL; GENES, REGULATOR; HERPESVIRUS 2, GALLID; IMMEDIATE-EARLY PROTEINS; MAREK DISEASE; PEPTIDES; PROMOTER REGIONS (GENETICS); RECOMBINANT PROTEINS; TRANS-ACTIVATION (GENETICS); UP-REGULATION; VIRAL PROTEINS;

GALLID HERPESVIRUS 2; GALLUS GALLUS; HUMAN HERPESVIRUS 1; SIMIAE; SIMIAN VIRUS 40; SIMPLEXVIRUS; UNIDENTIFIED BACULOVIRUS;

EID: 0037006942     PISSN: 03781135     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1135(01)00522-3     Document Type: Article

References (40)

1. The genome of turkey herpesvirus
2. Agent of Marek's disease in tissue culture
3. The attenuation, with loss of oncogenicity, of the herpes-type virus of Marek's disease (strain HPRS-16) on passage in cell culture
4. Immunization against Marek's disease using a live attenuated virus
5. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector
6. Enhancement of gene expression by Marek's disease virus homologue of the herpes simplex virus-1 ICP4
7. Expression of the endogenous Marek's disease virus ICP4 homolog (MDV ICP4) gene is enhanced in latently infected cells by transient transfection with the recombinant MDV ICP4 gene
8. Functional and genetic analysis of the role of Vmw 110 in herpes simplex virus replication
9. Identification of a novel bovine herpesvirus type 1 immediate-early infected cell protein
10. Onset of protective immunity in chicks after vaccination with a recombinant herpesvirus of turkeys vaccine expressing Newcastle disease virus fusion and hemagglutinin-neuraminidase antigens
11. Identification and characterization of the ICP22 protein of equine herpesvirus 1
12. Characterization of the regulatory function of the ICP22 protein of equine herpesvirus type 1
13. Heterogeneity of feline herpesvirus type 1 strains
14. A complete genomic DNA sequence of Marek's disease virus type 2, strain HPRS24
15. Marek's disease virus serotype 2 glycoprotein I gene: Nucleotide sequence and expression by a recombinant baculovirus
16. Epstein-Barr virus-encoded protein kinase BGLF4 mediates hyperphosphorylation of cellular elongation factor 1δ (EF-1δ): EF-1δ is universally modified by conserved protein kinases of herpesviruses in mammalian cells
17. Herpes simplex virus 1 alpha regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3
18. Interaction of epstein-barr virus nuclear antigen leader protein (EBNA-LP) with HS1-associated protein X-1: Implication of cytoplasmic function of EBNA-LP
19. Herpes simplex virus 1 alpha regulatory protein ICP0 functionally interacts with cellular transcription factor BMAL1
20. Casein kinase II specifically nucleotidylylates in vitro the amino acid sequence of the protein encoded by the alpha 22 gene of herpes simplex virus 1
21. Protection of chickens from Newcastle and Marek's diseases with a recombinant herpesvirus of turkeys vaccine expressing the Newcastle disease virus fusion protein
22. Efficacy in chickens of a herpesvirus of turkeys recombinant vaccine containing the fusion gene of Newcastle disease virus: Onset of protection and effect of maternal antibodies
23. Studies on the etiology of Marek's disease. II. Finding of a herpesvirus in cell culture
24. Enhanced expression of the Marek's disease virus-specific phosphoproteins after stable transfection of MSB-1 cells with the Marek's disease virus homologue of ICP4
25. The UL13 gene of herpes simplex virus 1 encodes the functions for posttranslational processing associated with phosphorylation of the regulatory protein alpha 22
26. Processing of the herpes simplex virus regulatory protein alpha 22 mediated by the UL13 protein kinase determines the accumulation of a subset of alpha and gamma mRNAs and proteins in infected cells
27. Transactivation activity of Meq, a Marek's disease herpesvirus bZIP protein persistently expressed in latently infected transformed T cells
28. Protective efficacy of a recombinant herpesvirus of turkeys as an in ovo vaccine against Newcastle and Marek's diseases in specific-pathogen-free chickens
29. Sequence determination and genetic content of an 8.9-kb restriction fragment in the short unique region and the internal inverted repeat of Marek's disease virus type 1 DNA
30. Marek's disease virus protein kinase gene identified within the short unique region of the viral genome is not essential for viral replication in cell culture and vaccine-induced immunity in chickens
31. Construction of recombinant Marek's disease virus type 1 (MDV1) expressing the Escherichia coli lacZ gene as a possible live vaccine vector: The US10 gene of MDV1 as a stable insertion site
32. Protection of chickens with or without maternal antibodies against both Marek's and Newcastle diseases by one-time vaccination with recombinant vaccine of Marek's disease virus type 1
33. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins
34. Herpes simplex virus 1 mutant deleted in the alpha 22 gene: Growth and gene expression in permissive and restrictive cells and establishment of latency in mice
35. Studies on the etiology of Marek's disease. I. Propagation of the agent in cell culture
36. Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies
37. SR alpha promoter: An efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukaemia virus type 1 long terminal repeat
38. The genome of a very virulent Marek's disease virus
39. Herpes simplex virus phosphoproteins. I. Phosphate cycles on and off some viral polypeptides and can alter their affinity for DNA
40. Protective efficacy of Marek's disease vaccines